Lyratherapeutics
Founded 2018 · 25 employees on LinkedIn · 1 known investors
Find your way into Lyratherapeutics
Lyra Therapeutics develops biocompatible mesh scaffolds for sustained drug delivery to the sinonasal passages, targeting treatment of chronic rhinosinusitis. The company's proprietary platform uses bioabsorbable polymers and engineered matrices to deliver medication over up to six months with a single administration.
Investors · 1
Frequently asked questions
- What does Lyratherapeutics do?
- Lyra Therapeutics develops biocompatible mesh scaffolds for sustained drug delivery to the sinonasal passages, targeting treatment of chronic rhinosinusitis. The company's proprietary platform uses bioabsorbable polymers and engineered matrices to deliver medication over up to six months with a single administration.
- Who are Lyratherapeutics's investors?
- Lyratherapeutics's investors include Broadview Ventures.